GSK3B and colonic neoplasm: Our previous investigation has demonstrated for the first time that siRNA against galectin-3 modulated GSK-3β phosphorylation and suppressed β-catenin expression, thus inhibiting epirubicin-triggered resistance via decreasing the expressions of cyclin D1, Bcl-2, c-Myc, P-gp, MRP1, and MRP2 in human colon cancer cells [17].